Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an, China.
Department of Medical Oncology, Senior Department of Oncology, Chinese People''s Liberation Army of China (PLA) General Hospital, The Fifth Medical Center, Beijing, China.
Front Immunol. 2022 May 2;13:865975. doi: 10.3389/fimmu.2022.865975. eCollection 2022.
As major post-translational modifications (PTMs), acetylation and deacetylation are significant factors in signal transmission and cellular metabolism, and are modulated by a dynamic process two pivotal categories of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). In previous studies, dysregulation of lysine acetylation and deacetylation has been reported to be associated with the genesis and development of malignancy. Scientists have recently explored acetylation/deacetylation patterns and prospective cancer therapy techniques, and the FDA has approved four HDAC inhibitors (HDACi) to be used in clinical treatment. In the present review, the most recent developments in the area of lysine acetylation/deacetylation alteration in cancer immunotherapy were investigated. Firstly, a brief explanation of the acetylation/deacetylation process and relevant indispensable enzymes that participate therein is provided. Subsequently, a multitude of specific immune-related molecules involved in the lysine acetylation/deacetylation process are listed in the context of cancer, in addition to several therapeutic strategies associated with lysine acetylation/deacetylation modification in cancer immunotherapy. Finally, a number of prospective research fields related to cancer immunotherapy concepts are offered with detailed analysis. Overall, the present review may provide a reference for researchers in the relevant field of study, with the aim of being instructive and meaningful to further research as well as the selection of potential targets and effective measures for future cancer immunotherapy strategies.
作为主要的翻译后修饰（PTMs），乙酰化和去乙酰化是信号转导和细胞代谢的重要因素，受两个关键酶类——组蛋白乙酰转移酶（HATs）和组蛋白去乙酰化酶（HDACs）的动态调节。在以前的研究中，赖氨酸乙酰化和去乙酰化的失调与恶性肿瘤的发生和发展有关。科学家们最近探索了乙酰化/去乙酰化模式和潜在的癌症治疗技术，美国食品和药物管理局（FDA）已经批准了四种 HDAC 抑制剂（HDACi）用于临床治疗。在本综述中，研究了赖氨酸乙酰化/去乙酰化改变在癌症免疫治疗中的最新进展。首先，简要解释了乙酰化/去乙酰化过程及其参与的必需酶。随后，列出了癌症中涉及赖氨酸乙酰化/去乙酰化过程的多种特定免疫相关分子，以及与癌症免疫治疗中赖氨酸乙酰化/去乙酰化修饰相关的几种治疗策略。最后，提出了与癌症免疫治疗概念相关的一些有前景的研究领域，并进行了详细分析。总的来说，本综述可能为相关研究领域的研究人员提供参考，为进一步研究以及未来癌症免疫治疗策略的潜在靶点和有效措施的选择提供指导和意义。
